Literature DB >> 23848504

Clinical outcome and predictors of survival in patients with pneumocystis jirovecii pneumonia--results of a tertiary referral centre.

Felicitas Roembke1, Hauke Sebastian Heinzow, Thomas Gosseling, Achim Heinecke, Dirk Domagk, Wolfram Domschke, Tobias Meister.   

Abstract

BACKGROUND AND AIMS: Pneumocystis jirovecii pneumonia also known as pneumocystis pneumonia (PCP) is an opportunistic respiratory infection in human immunodeficiency virus (HIV) patients that may also develop in non-HIV immunocompromised persons. The aim of our study was to evaluate mortality predictors of PCP patients in a tertiary referral centre.
METHODS: Fifty-one patients with symptomatic PCP were enrolled in the study. The patients had either HIV infection (n = 21) or other immunosuppressive conditions (n = 30). Baseline characteristics (e.g. age, sex and underlying disease) were retrieved. Kaplan-Meier analysis was employed to calculate survival. Comparisons were made by log-rank test. A multivariate analysis of factors influencing survival was carried out using the Cox regression model. Chi-squared test and Wilcoxon-Mann-Whitney test was applied as appropriate.
RESULTS: The median survival time for the HIV group was >120 months compared with 3 months for the non-HIV group (P = 0.009). Three-month survival probability was also significantly greater in the HIV group compared with the non-HIV group (90% vs 41%, P = 0.002). In univariate log-rank test, intensive care unit (ICU) necessity, HIV negativity, age >50 years, haemoglobin <10g/dl, C-reactive protein >5 mg/dL and multiple comorbidities were significant negative predictors of survival. In the Cox regression model, ICU and HIV statuses turned out to be independent prognostic factors of survival.
CONCLUSION: PCP is a serious problem in non-HIV immunocompromised patients in whom survival outcomes are worse than those in HIV patients.
© 2013 John Wiley & Sons Ltd.

Entities:  

Keywords:  HIV; non-HIV; pneumocystis pneumonia; predictors of survival

Mesh:

Year:  2013        PMID: 23848504     DOI: 10.1111/crj.12042

Source DB:  PubMed          Journal:  Clin Respir J        ISSN: 1752-6981            Impact factor:   2.570


  6 in total

1.  Incidence, clinical presentation, and outcomes of Pneumocystis pneumonia when utilizing Polymerase Chain Reaction-based diagnosis in patients with Hodgkin lymphoma.

Authors:  Jason N Barreto; Carrie A Thompson; Patrick M Wieruszewski; Amanda G Pawlenty; Kristin C Mara; Ashley L Potter; Pritish K Tosh; Andrew H Limper
Journal:  Leuk Lymphoma       Date:  2020-07-05

2.  Efficacy of caspofungin combined with trimethoprim/sulfamethoxazole as first-line therapy to treat non-HIV patients with severe pneumocystis pneumonia.

Authors:  Gensheng Zhang; Miaomiao Chen; Shufang Zhang; Hongwei Zhou; Xiaozhen Ji; Jiachang Cai; Tianzheng Lou; Wei Cui; Ning Zhang
Journal:  Exp Ther Med       Date:  2017-11-16       Impact factor: 2.447

3.  Caspofungin combined with TMP/SMZ as a first-line therapy for moderate-to-severe PCP in patients with human immunodeficiency virus infection.

Authors:  Q Tian; J Si; F Jiang; R Xu; B Wei; B Huang; Q Li; Z Jiang; T Zhao
Journal:  HIV Med       Date:  2020-12-04       Impact factor: 3.180

4.  Pneumocystis Jirovecii Pneumonia in a Kidney Transplant Recipient 13 Months after Transplantation: A Case Report and Literature Review.

Authors:  Dominykas Varnas; Augustina Jankauskienė
Journal:  Acta Med Litu       Date:  2021-01-25

5.  Prognostic factors for severe Pneumocystis jiroveci pneumonia of non-HIV patients in intensive care unit: a bicentric retrospective study.

Authors:  Li Weng; Xu Huang; Lie Chen; Li-Qin Feng; Wei Jiang; Xiao-Yun Hu; Jin-Min Peng; Chun-Yao Wang; Qing-Yuan Zhan; Bin Du
Journal:  BMC Infect Dis       Date:  2016-09-29       Impact factor: 3.090

6.  Pneumocystis jirovecii pneumonia (PCP) PCR-negative conversion predicts prognosis of HIV-negative patients with PCP and acute respiratory failure.

Authors:  Ji Soo Choi; Sang Hoon Lee; Ah Young Leem; Joo Han Song; Song Yee Kim; Kyung Soo Chung; Ji Ye Jung; Young Ae Kang; Young Sam Kim; Joon Chang; Moo Suk Park
Journal:  PLoS One       Date:  2018-10-25       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.